Cell Cycle/Checkpoint

The cell cycle is consisted of 4 main phases: Gap 1 (G1), DNA replication (S), Gap 2 (G2), and mitosis (M). There are “checkpoints” mechanism regulates the transition between these phases, at the G1/S boundary, in the S-phase and during G2/M phases. Cell can only pass through these checkpoints when signaling factors are activated and free of DNA damage. Important proteins that control cell cycle events and checkpoints are cullins, cyclins, cyclin-dependent kinases (Cdks), p53 and their inhibitors etc. Cdks family (Cdk2, Cdk3, Cdk4 and Cdk6) are Ser/Thr kinases that regulate cell cycle progression in association with cyclin binding partners (cyclin D, cyclin E and cyclin A) during all four phases. p53 halts the cell cycle if the DNA is damaged and allowing time for DNA repair to progress; it can also initiate apoptosis if DNA damage is too severe to be repaired.
-   A4116 Danusertib (PHA-739358)2 CitationTarget: Aurora KinasesSummary: Pan-aurora kinase inhibitor A4116 Danusertib (PHA-739358)2 CitationTarget: Aurora KinasesSummary: Pan-aurora kinase inhibitor
-   A4393 Paclitaxel (Taxol)27 CitationTarget: Microtubules/TubulinsSummary: microtubule depolymerization inhibitor A4393 Paclitaxel (Taxol)27 CitationTarget: Microtubules/TubulinsSummary: microtubule depolymerization inhibitor
-   A3303 CGP60474Summary: CDKs and PKC inhibitor, potent A3303 CGP60474Summary: CDKs and PKC inhibitor, potent
-   A5734 Fasudil (HA-1077) HCl1 CitationTarget: ROCKSummary: Protein kinase inhibitor A5734 Fasudil (HA-1077) HCl1 CitationTarget: ROCKSummary: Protein kinase inhibitor
-   B1437 PF-477736Target: ChkSummary: Chk1 inhibitor B1437 PF-477736Target: ChkSummary: Chk1 inhibitor
-   B1288 RigosertibTarget: PI3K|PLKSummary: PI3K/PLK1 inhibitor B1288 RigosertibTarget: PI3K|PLKSummary: PI3K/PLK1 inhibitor
-   C3687 CCG-1006021 CitationSummary: Rho pathway inhibitor C3687 CCG-1006021 CitationSummary: Rho pathway inhibitor
-   A4115 JNJ-77066211 CitationTarget: Cyclin-Dependent Kinases|Aurora KinasesSummary: Potent CDK/Aurora kinase inhibitor A4115 JNJ-77066211 CitationTarget: Cyclin-Dependent Kinases|Aurora KinasesSummary: Potent CDK/Aurora kinase inhibitor
-   A3295 CDK9 inhibitor 2Summary: CDK9 inhibitor A3295 CDK9 inhibitor 2Summary: CDK9 inhibitor
-   A3631 Monomethyl auristatin ESummary: A type of antimitotic agent that can also be widely used as a cytotoxic component for the preparation of antibody-drug conjugates (ADCs) for cancer research. A3631 Monomethyl auristatin ESummary: A type of antimitotic agent that can also be widely used as a cytotoxic component for the preparation of antibody-drug conjugates (ADCs) for cancer research.
